Amphastar Pharmaceuticals, Inc. (AMPH) bonds
AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3030% below fair value
$29.37+0.50 (+1.73%)
Close on Nov 13, 2026Market cap $1.25BP/E 13.3Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
Total debt
$613.00M
$2.51M due within a year
Net debt
$408.41M
After $204.59M of cash
Implied interest rate
4.20%
FY2025 interest ÷ average debt
Interest coverage
5.5×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2025
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Amphastar Pharmaceuticals's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| 2029 Convertible Notes Convertible at $63 a share | 2.00% | $345.00M | $345.00M |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Drawn | Expires |
|---|---|---|---|
| French Government Loan 4 - Due December 2026 | – | $59.00K | Dec 31, 2026 |
| French Government Loan 5 - Due December 2026 | – | $56.00K | Dec 31, 2026 |
| Term Loan - Due June 2028 | – | $250.00M | Jun 30, 2028 |
| Line of Credit Due November 2033 | $40.00M | – | Nov 30, 2033 |
| Line of Credit | – | $25.05M | – |
| Revolving Credit Facility | $200.00M | – | – |
| Secured Debt | $500.00M | – | – |
See a number that looks wrong?